Home > Articles > Retatrutide vs tirzepatide: how the trial designs and data compare
Prepared by: Research Desk
Prepared by: Research Desk. Sources are linked for verification.
Status: Investigational. Retatrutide is not approved by the FDA or, as far as we know, by any other regulator. The FDA page on unapproved GLP-1 drugs states that retatrutide cannot be used in compounding under federal law [1]. The same page discusses tirzepatide as an ingredient of FDA-approved drugs [1]. Full details are on our approval status page.
"Retatrutide vs tirzepatide" is one of the most searched questions about retatrutide. A complete answer is not yet possible. As of 19 October 2026 we are not aware of any peer-reviewed head-to-head results comparing the two molecules. What can be compared is how their research programs were built: who was enrolled, what was measured, for how long, and against what comparator. This page sets those designs side by side. It also explains why lining up headline numbers from separate trials is unreliable.
This page reports published research and trial registrations only. It does not offer guidance on using either drug. Our sourcing standards are described on the About TripleReta page.
The comparison at a glance
Retatrutide | Tirzepatide | |
|---|---|---|
Receptors targeted | GIP, GLP-1 and glucagon [2][3] | Commonly described as a dual GIP and GLP-1 receptor agonist (see our guide) |
Regulatory status | Investigational; FDA says it cannot be compounded [1] | Ingredient of FDA-approved drugs; FDA has raised concerns about unapproved versions [1] |
Phase 2 publications | Obesity (NEJM, 2023) [2]; type 2 diabetes (Lancet, 2023) [3]; liver fat (Nat Med, 2024) [4] | Not covered on this page |
Phase 3 program | TRIUMPH [5][6][7][8][9][10] | SURMOUNT (example in this source set: SURMOUNT-1 body-composition analysis [11]) |
Direct comparison | TRIUMPH-5, registered on ClinicalTrials.gov [10] | Comparator in TRIUMPH-5 [10] |
How the mechanisms differ
Both molecules are single peptides that act on more than one hormone receptor. Retatrutide's phase 2 obesity paper describes it as a "triple-hormone-receptor agonist" [2], and the type 2 diabetes paper calls it "a GIP, GLP-1 and glucagon receptor agonist" [3]. Tirzepatide is generally described as acting on the GIP and GLP-1 receptors only. None of the sources cited on this page sets out tirzepatide's receptor profile directly, so read that description as background rather than a sourced finding here. Our retatrutide guide covers the receptor targets in more depth.
On that description, glucagon-receptor activity is the main pharmacological difference between the two. Liver fat is one area where retatrutide has been studied specifically: a randomized phase 2a trial in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) examined liver-fat outcomes [4]. A difference in mechanism is a hypothesis, though, not a result. Whether it produces measurable differences from tirzepatide in people is exactly what a direct trial has to show.
Retatrutide's evidence, trial by trial
Phase 2, obesity. This randomized, placebo-controlled trial enrolled 338 adults with obesity, or with overweight plus at least one weight-related condition. It ran for 48 weeks. Several retatrutide groups were compared with placebo. The largest mean reduction in body weight reported in any retatrutide group was 24.2%, against 2.1% with placebo [2]. These are phase 2 figures from a trial designed to explore a range of regimens, and phase 3 trials are larger and longer.
Phase 2, type 2 diabetes. This was a randomised, double-blind trial conducted in the USA. It was placebo-controlled and also active-controlled, so retatrutide was measured against an existing therapy as well as against placebo [3]. Glycaemic and body-weight outcomes in people with diabetes are not directly comparable with outcomes in people without diabetes.
Phase 2a, liver fat. This randomized trial focused on liver fat in MASLD [4]. Its endpoints were different from those of the obesity trials.
TRIUMPH phase 3 program. Each study has its own ClinicalTrials.gov record:
TRIUMPH-1 (NCT05929066): obesity or overweight. The registry record sets out its design, outcomes and status [5].
TRIUMPH-2 (NCT05929079): obesity with type 2 diabetes [6]. Published in The Lancet in 2026 as a double-blind, parallel-group, randomised, placebo-controlled phase 3 trial [7].
TRIUMPH-3 (NCT05882045): obesity with cardiovascular disease [8].
TRIUMPH-4 (NCT05931367): obesity with knee osteoarthritis [9].
TRIUMPH-5 (NCT06662383): the registered comparison with tirzepatide [10].
Tirzepatide's evidence in this source set
Tirzepatide has a large published phase 3 literature, the SURMOUNT program. This page draws on only a few items connected to it.
One is a body-composition analysis from SURMOUNT-1 in adults with obesity or overweight. It reported how the weight reduction seen with tirzepatide was divided between fat mass and lean mass [11]. This matters for comparison because total body weight is only one measure. Two drugs with similar weight changes could still differ in body composition. A matched comparison would need the same measurement method, the same timepoints and similar populations.
A 2024 Diabetes Care article asks whether resistance exercise can shape body-composition changes during incretin-based weight-loss pharmacotherapy [12]. It shows that body composition is an active research question across this whole drug class, not only for one molecule.
A 2025 systematic review in Annals of Internal Medicine pooled randomized controlled trials of GLP-1 receptor agonists for weight loss in adults without diabetes [13]. Systematic reviews like this give context on typical effect sizes and adverse-event patterns across the class. They cannot settle how one specific molecule compares with another unless the two were tested in the same trial.
Why cross-trial comparisons mislead
It is tempting to put retatrutide's largest phase 2 figure next to a tirzepatide phase 3 figure and declare a winner. Standard trial-design reasoning cautions against this for several reasons.
Different populations. Baseline weight, diabetes status, age and sex mix all affect outcomes. Retatrutide's own phase 2 trials show this: the obesity trial [2] and the type 2 diabetes trial [3] enrolled different people and measured different primary outcomes.
Different durations. A 48-week phase 2 result and a longer phase 3 result capture different points on the weight curve.
Different phases. Phase 2 trials are smaller and explore several regimens. Phase 3 trials are designed to confirm a result. The "best" group in a phase 2 trial is selected after the fact, so its figure tends to look more favourable.
Different estimands. Obesity trials often report more than one estimand. One estimate assumes participants stayed on the study drug. Another counts everyone randomized, whatever they did after randomization. These two numbers can differ noticeably, and mixing them across trials distorts the picture.
Placebo response and blinding. Placebo-group changes vary from trial to trial. The difference from placebo is more informative than the raw change in the active group.
The same caution applies to side effects. Adverse-event rates depend on how events were collected, how quickly participants moved through the study regimen, and how long they were followed. A dedicated page on retatrutide side effects in trials is planned.
What TRIUMPH-5 is designed to answer
TRIUMPH-5 (NCT06662383) is the registered study that compares retatrutide directly with tirzepatide [10]. In a randomized head-to-head design, both groups are enrolled under the same criteria, followed on the same schedule and measured with the same methods. That removes most of the cross-trial problems listed above. The ClinicalTrials.gov record shows the study's current recruitment status, primary outcome, enrollment target and estimated completion dates. These fields can change, so the record's update history is worth checking.
On regulation, a May 2026 industry pipeline summary listed an FDA decision on retatrutide as a 2027 event [14]. Our approval status page tracks that timeline as new information appears.
A note on products sold online
The FDA page on unapproved GLP-1 drugs addresses retatrutide by name [1]:
"Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition."
The same FDA page describes warnings issued to companies marketing or distributing retatrutide [1]. FDA updates that page over time, so the linked version is the authoritative wording. Any product sold online as "retatrutide" falls outside the trials described on this page. Its contents are unknown.
Further reading on trial methods
Most confusion in comparison coverage comes from trial methods, not biology. Readers who want to judge comparison claims on their own need a working grasp of randomization, blinding, estimands, confidence intervals and the limits of indirect comparisons.
A good methods book makes these ideas concrete with worked examples from published trials. Books differ a great deal in level, so the selection criteria below matter more than any single title.
When comparing books in this category, these neutral criteria separate useful titles from outdated ones. None of them depends on a particular publisher.
Edition date. Estimand concepts were formalised relatively recently, so older editions may not cover them.
Level. Some books assume calculus and statistical software; others are written for non-statisticians.
Coverage. Look for chapters on non-inferiority and head-to-head designs, indirect comparison and network meta-analysis, and handling of missing data.
Worked examples. Real published trials teach more than invented datasets.
Format and price. Compare print, e-book and audio availability, and whether the listed price is shown clearly before checkout.
Frequently asked questions
Has retatrutide been compared directly with tirzepatide?
A direct comparison is registered as TRIUMPH-5 (NCT06662383) on ClinicalTrials.gov [10]. As of 19 October 2026 we are not aware of peer-reviewed results from that study. Until it reports, any "retatrutide vs tirzepatide" figure comes from separate trials.
Why can't the phase 2 retatrutide result be compared with tirzepatide's phase 3 results?
The trials differ in phase, size, duration, population and often estimand. The 24.2% figure from the phase 2 obesity trial is the largest mean change among several groups over 48 weeks [2]. Phase 3 trials are built differently, so setting the numbers side by side mixes unlike measurements.
Is retatrutide approved like tirzepatide?
No. Retatrutide is investigational. FDA states it cannot be used in compounding under federal law and is not a component of any FDA-approved drug [1]. A May 2026 pipeline summary listed a possible FDA decision as a 2027 event [14].
Last updated: 19 October 2026.
Related on this site
Is retatrutide FDA approved? Legal status and approval timeline
Retatrutide: mechanism, trial findings and side effects explained
How to read retatrutide trial results: endpoints, placebo, dropouts
Books about clinical trials: a reading list for following research
Not medical advice. This page reports published research and regulatory records for information only.
Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.
Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.